4 Analysts Have This to Say About NGM Biopharmaceuticals
Within the last quarter, NGM Biopharmaceuticals (NASDAQ:NGM) has observed the following analyst ratings:
Analyst Ratings for NGM Biopharmaceuticals
NGM Biopharmaceuticals (NASDAQ:NGM) has observed the following analyst ratings within the last quarter:
Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From Yesterday
Gainers
Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case.
Goldman Sachs Downgrades NGM Biopharmaceuticals to Neutral, Lowers Price Target to $4
Goldman Sachs analyst Paul Choi downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Buy to Neutral and lowers the price target from $29 to $4.
Dow Rises Over 2%; S&P 500 Up 100 Points
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 300 points on Monday.
Piper Sandler Downgrades NGM Biopharmaceuticals to Neutral
Piper Sandler analyst Swapnil Malekar downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Overweight to Neutral.
Jefferies Downgrades NGM Biopharmaceuticals to Hold
Jefferies analyst Dennis Ding downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Buy to Hold.
Why Bank of America Shares Are Trading Higher? Here Are 66 Stocks Moving In Monday’s Mid-Day Session
Gainers
FedNat Holding Company (NASDAQ: FNHC) shares rose 78.9% to $0.93 after jumping 48% on Friday.
How Is The Market Feeling About NGM Biopharmaceuticals?
NGM Biopharmaceuticals's (NASDAQ:NGM) short percent of float has risen 23.05% since its last report. The company recently reported that it has 2.67 million shares sold short, which is 12.28% of all regular shares that are available for trading.